SCHEMBL3136039

SCHEMBL3136039

Cc1ccc(N)cc1N1Cc2cnc(Nc3cccc(N(C)C)c3)nc2N(C)C1=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BMX P51813 14/20 0.57
TNK2 Q07912 7/20 0.54
MAP4K2 Q12851 7/20 0.54
ABL1 P00519 3/20 0.54
BCR P11274 1/20 0.51
RIPK1 Q13546 1/20 0.51
RIPK3 Q9Y572 1/20 0.51
FGFR4 P22455 1/20 0.51
MAPK3 P27361 1/20 0.48
LCK P06239 1/20 0.48
FES P07332 1/20 0.48
RET P07949 1/20 0.48
PDGFRB P09619 1/20 0.48
KIT P10721 1/20 0.48
FGFR1 P11362 1/20 0.48
SRC P12931 1/20 0.48
PDGFRA P16234 1/20 0.48
FLT1 P17948 1/20 0.48
FGFR3 P22607 1/20 0.48
EPHA3 P29320 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3139703 0.90 BMX (0.59) BMXTNK2MAP4K2ABL1BCR
SCHEMBL3144304 0.88 BMX (0.53) BMXTNK2MAP4K2ABL1BCR
SCHEMBL13521817 0.88 BMX (0.65) BMXTNK2MAP4K2ABL1BCR
SCHEMBL13521818 0.85 TNK2 (0.77) BMXTNK2MAP4K2ABL1BCR
SCHEMBL19865443 0.83 TNK2 (0.72) BMXTNK2MAP4K2ABL1BCR
SCHEMBL3139709 0.82 TNK2 (0.73) BMXTNK2MAP4K2ABL1BCR
SCHEMBL3135665 0.81 TNK2 (0.84) BMXTNK2MAP4K2ABL1BCR
SCHEMBL3827669 0.80 TNK2 (0.66) BMXTNK2MAP4K2ABL1BCR
SCHEMBL3139610 0.78 TNK2 (0.72) BMXTNK2MAP4K2ABL1BCR
SCHEMBL14213438 0.78 BMX (0.60) BMXTNK2MAP4K2ABL1BCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642255-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2010-01-05 US disclosed
EP-1651648-A4 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2009-09-02 EP disclosed
US-20080221098-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2008-09-11 US disclosed
US-7371750-B2 Diseases with abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, alpha and beta SAPK2 kinases; antiproliferative; pyrrolo[2,3-d]pyrimidine-7-carboxylic acid [3-phenylcarbamoyl-phenyl]-amides and pyrrolo[3,2-c]pyridine analogs IRM LLC (BM) 2008-05-13 US disclosed
EP-1651648-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2006-05-03 EP disclosed
US-20050222177-A1 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2005-10-06 US disclosed
WO-2005011597-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2005-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222177-A1 Compounds and compositions as protein kinase inhibitors BMX, FES, FRK BMX 1/4885TNK2 203/4885MAP4K2 37/4885
US-20080221098-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS BMX, FES, FRK BMX 1/4885TNK2 203/4885MAP4K2 37/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.